Active Ingredient(s): Afamelanotide
FDA Approved: * October 8, 2019
Pharm Company: * CLIVUNEL INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Scenesse Overview

Afamelanotide, sold under the brand name Scenesse, is a synthetic peptide and analogue of α-melanocyte stimulating hormone used to prevent skin damage from the sun in people with erythropoietic protoporphyria in the European Union since January 2015, and the United States since October 2019. As a medication it is administered in subcutaneous implant form; the implant lasts for two months.[medical citation needed] The U.S. Food and Drug Administration (FDA) considers it ...

Read more Scenesse Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Scenesse Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Implant: 16mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Scenesse: (2 results)

Sorted by National Drug Code
  • 73372-0116 Scenesse 16 mg/16mg Subcutaneous Implant by Clinuvel Inc.
  • 73850-0116 Scenesse 16 mg/16mg Subcutaneous Implant by Csm Clinical Supplies Management Europe Gmbh

Other drugs which contain Afamelanotide or a similar ingredient: (1 result)